Cellectar biosciences and city of hope cancer center enter collaboration to evaluate iopofosine i 131 in mycosis fungoides

Opportunity for iopofosine expansion within areas of high unmet need in non-hodgkin's lymphoma establishes partnership with one of the largest cancer research and treatment organizations in the u.s. florham park, n.j., may 29, 2024 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, announced today a strategic partnership with city of hope cancer center, one of the largest cancer research and treatment organizations in the united states.
CLRB Ratings Summary
CLRB Quant Ranking